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Abstract
Aim: The aim of this study is to provide adequate protection to ewes and their lambs against Foot and Mouth disease (FMD) 
and Rift Valley Fever (RVF).
Materials and Methods: A combined inactivated FMD and RVF oil vaccine was prepared successfully. Such vaccine 
was found to be free from foreign contaminants, safe and potent as determined by quality control tests such as challenge 
protection percentage for FMD and mice ED50 for RVF. Vaccination of pregnant ewes with the prepared combined vaccine 
and determination of the antibody level via serum neutralization test (SNT) and Enzyme Linked immune sorbent assay 
(ELISA) in the vaccinated pregnant ewes and their lambs.
Results: Vaccination of pregnant ewes revealed that these ewes exhibited high levels of specific antibodies against the 
included vaccine antigens (Foot and Mouth disease virus type A Iran O5, O PanAsia and SAT2/EGY/2012 and RVFV-ZH501). 
FMD antibodies recorded their peaks by the 10th week post vaccination while those of RVF recorded their peaks by the 
12th week post vaccination then all antibodies began to decrease gradually to reach their lowest protective titers for FMD by 
the 32nd week post vaccination and those for RVF by the 34th week post vaccination. Potency test of the prepared combined 
vaccine expressed as protection percentage of vaccinated sheep against target virulent FMD virus serotypes reflected a 
protection percentage of 80% against type O and SAT2 and 100% against A while for RVF, the mice ED50 was found to 
be 0.009 indicating the potency of the prepared vaccine. The antibody titer in serum and colostrum of vaccinated pregnant 
ewes at day of parturition (10-12 week post vaccination) recorded a high titer against FMD serotype (O), serotype (A), 
serotype (SAT2) and against RVF. It was noticed that the colostrum antibody titers were slightly higher than those in the sera 
of vaccinated ewes at time of parturition. The newly born lambs from vaccinated ewes, exhibited good levels of maternal 
immunity against the included antigens through suckling their mother colostrum by the 24 hrs. post parturition. The newly 
born lambs recorded their highest level by 1 week of birth and lasted within a protective level up to 11-12 week of birth.
Conclusion: Using of FMD/RVF combined vaccine provided a sufficient immune status for pregnant ewes as well as for 
their lambs. Vaccination of newly born lambs should be carried out by the 4th month of birth.
Keywords: FMD, RVF, combined vaccine, pregnant ewes, new born lambs, SNT, ELISA.
Introduction
Foot and mouth disease (FMD) is a highly infec-
tious disease of cloven footed animals including cattle, 
sheep, goats, pigs and also wild animals. Foot and mouth 
disease virus (FMDV) is the main etiologic agent of the 
disease which causes an acute disease characterized by 
fever, lameness and vesicular lesions on the feet, tongue, 
snout and teats, with high morbidity and low mortality [1].
The etiological agent, FMDV belongs to genus: 
Aphthovirus, family: Picornaviridae. The virus exists 
in the form of seven serologically and genetically 
distinguishable types, namely, O, A, C, Asia1, SAT1, 
SAT2, and SAT3, also a large number of subtypes 
have evolved within each serotype [2]. In Egypt, the 
disease is enzootic and many outbreaks have been 
reported since 1950. FMD serotypes SAT2, A and 
O were last reported in years 1950, 1972 and 2000 
respectively [3]. The type O was the most preva-
lent since 1960 and onwards [4,5]. Serotype A was 
reintroduced to Egypt during 2006 through live ani-
mal’s importation where sever clinical signs were 
recorded among cattle and buffaloes [6]. In addition, 
serotype SAT2 of FMD virus was later introduced to 
Egypt during 2012 also through live animal’s impor-
tation [7]. Live animals importation is considered as 
a main risk factor in many old and new outbreaks in 
Egypt.
Control of FMD in animals was considered to be 
the corner stone to eliminate the disease in endemic 
areas through effective vaccination of susceptible ani-
mals [1], beside controlling the in and out motion of 
the live susceptible animals.
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Rift valley fever (RVF) is an acute viral dis-
ease that can cause severe disease in domestic ani-
mals as buffalo, camels, cattle, goats and sheep) and 
human. Disease in these species characterized by 
fever, severe illness, abortions, and a high morbidity 
and mortality rate. The etiologic cause is RVF virus 
(RVFV) which belongs to genus: Phlebovirus, family: 
Bunyaviridae [8,9]. The most significant economic 
losses of RVF is due to death in young animals and 
abortion among infected livestock [10].
Egypt is the most northern, and populous nation 
to have suffered from RVF and the human illness and 
death experienced there during the1977-1978 epizootic 
which was of unprecedented severity. In Egypt, RVF 
outbreaks had occurred in 1993, 1999, and most recently 
in 2003. In most cases these outbreaks were believed to 
have begun as epizootics among sheep, goats, cattle, and 
camels, which serve as amplifying hosts of the virus. 
The outbreaks of RVF in Upper Egypt during 1977 were 
preceded by epizootics that occurred to the south of 
Egypt in Sudan, Kenya, and Uganda, and were thought 
to result from the movement of herd animals into Egypt 
from the south [11,12]. The most common risk factor in 
Egypt between FMD and RVF is the movement of herd 
animals from another neighbor endemic areas.
Vaccine oil adjuvant is very important factor 
affecting the immune response and stimulate spe-
cific component either humeral or cell mediated 
immunity [13]. An oily vaccine was prepared by 
using Montanide oil as adjuvant to FMD, combined 
FMD with RVF and RVF vaccines giving high titer 
of antibodies and long duration of antibodies [14]. 
Furthermore, Montanide oil adjuvant for inactivated 
RVF vaccine induced early immune response in sheep 
rather than the alum gel [15]. As well as, it was suf-
ficient to protect the animal all over the year with 
only one vaccine dose rather than the alum gel which 
needed 2nd booster dose to maintain the protection all 
over the year.
A combined vaccine is that one consists of 2 or 
more separate immunogens physically combined into 
a single product [16]. Several benefits of a combined 
vaccine must be fulfilled as aiming to prevent multi-
ple diseases caused by different organisms [17] and 
also reducing the number of injections and therefore 
the degree of pain and side effect of repeated vacci-
nation. Also the result of this combination must be 
linked with the humeral immune response against the 
targeted organisms. The combined vaccine against 
FMD/RVF has been studied before and revealed an 
efficient humeral immune response against FMDV 
and RVFV in comparison with the single one [18].
The present study was intended to study the 
acquired maternal immunity induced by ISA206 oil 
FMD/RVF combined vaccine in new born lambs from 
vaccinated pregnant ewes so as to complete the scope 
of humeral immunity not only for ewes but also for 
their lambs and also to determine the most suitable time 
for the first immunization of the newly born lambs.
Material and Methods
Ethical approval
The experiment was carried out according to the 
protocol of Institutional Animal Ethics Committee 
and the authors had a permission of the animal owners 
at the private farms.
Animals
Sheep
Thirty-three native breed sheep were found to 
be serologically negative for the presence of antibod-
ies against FMDV type A, O or SAT2 and antibodies 
against RVF as proved by SNT and ELISA. These ani-
mals were classified as demonstrated in Figure-1.
New born lambs
Fifteen lambs born to previously vaccinated and 
control ewes were used for determination of maternal 
derived immunity against FMDV type A, O or SAT2 
and RVFV. These lambs suckled colostrum from their 
ewes immediately post parturition.
Suckling baby mice
Suckling Swiss baby mice, 2-4 days old, (Charles 
River Strain, USA) were used for the safety of the pre-
pared vaccine.
Weaned mice
Swiss albino weaned mice; 21-28 days old supplied 
by the Laboratory Animal Breeding Unit, Veterinary 
Serum and Vaccine Research Institute, Abbasia, Cairo, 
Egypt were used for titration of the virus, testing the 
potency of the prepared vaccine for RVF via ED50.
Samples
Serum samples
•  Serum samples were collected from pregnant 
ewes pre vaccination and weekly post vaccina-
tion for 10 weeks and then every 2 weeks up to 
36 weeks post vaccination
•  Serum samples collected from new born lambs 
weekly till 13 weeks after birth.
All the serum samples were tested for the pres-
ence of derived acquired maternal antibodies either 
against FMDV (A, O and SAT2) and RVFV using 
SNT and ELISA.
Colostrum samples
Colostrum samples were collected from ewes at 
the 24 h post parturition. These samples treated with 
renin and stored at −20°C until detection of antibody 
titer against FMDV and RVFV by SNT and ELISA.
Cell culture
Baby Hamster kidney cell line (BHK21) Clone 
13 obtained from Veterinary Serum and Vaccine 
Research Institute, Abbasia, Cairo using Eagl’s 
medium with 8-10% bovine serum as described by 
Xuan et al. [19] used for application of SNT, virus 
titration and vaccine preparation.Available at www.veterinaryworld.org/Vol.7/November-2014/4.pdf
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Viruses
FMD virus strains
Local FMD virus typ    e’s O pan Asia, A Iran 
O5 and SAT2/EGY/2012 propagated in BHK21 
cell line monolayer cultures were used for prepa-
ration of virus infected fluids and supplied by the 
Department of FMD Research, Veterinary Serum 
and Vaccine Research Institute. The titer of the 
three types was 9 log10 TCID50/ml as calculated by 
Reed and Muench [20] with CF value 1/64 detected 
according to [21].
RVF virus (ZH 501)
RVF virus was supplied by RVF Research 
Department, Veterinary Serum and Vaccine Research 
Institute, Abbasia Cairo with a titter 108.5 TCID50/ml fol-
lowing the techniques recommended by El-Nimr [22]. 
The antigen was stored at −70°C.
Virus purification
Aseptically, the harvested culture media from 
FMD and RVF virus infected BHK21 cell cultures 
were centrifuged in a cooling centrifuge at 3000 rpm 
for 20 min to remove cell debris.
Virus concentration
The tissue culture viral fluids of the three 
serotypes of FMDV (O pan Asia-2, A Iran O5 and 
SAT2/EGY/2012) and RVFV were centrifuged at 
7000 revolution/min for 30 min and then concen-
trated by PEG-6000 to reach to 1/10 of its original 
volume [18].
Virus inactivation
1% M Binary ethylenamine (BEI) in 0.2N 
NaOH was added to the virus suspension to give 
final concentration of 0.001 M of BEI. The virus and 
BEI mixture were mixed well and the pH adjusted to 
8.0 by sodium bicarbonate. The virus was placed on 
a magnetic stirrer in the incubator at 37°C for 18 h 
for inactivation. Sodium thiosulphate was added in a 
final concentration of 2% to neutralize the BEI action 
according to [23].
Formulation of FMD/RVF combined vaccine with 
Montanide ISA 206
The combined vaccine was prepared by mixing 
equal volumes of inactivated FMD virus strains and 
inactivated RVF virus. That aqueous antigen mixture 
was added in equal weight (w/w) to Montanide ISA 
206 oil phase and mixed thoroughly [18].
Evaluation of the prepared combined vaccine
Sterility test
The prepared combined vaccine was tested for 
its freedom of aerobic and anaerobic bacteria, fungal 
and mycoplasma contaminants where vaccine samples 
were cultured on thioglycolate broth, Sabouraud’s, 
Nutrient agar; phenol dextrose media and mycoplasma 
medium according to [8,24].
Safety test in baby mice
Three to five days old Swiss Albino suckling 
mice were used for the safety test of inactivated FMD 
and RVF viruses according to [25].
Potency test
Determination of mice ED50 for RVF
Fivefold dilutions of the vaccine were prepared 
in suitable media starting from 1:1 to 1:625. Five 
groups of weaned mice (21-28 days old) were used 
for each dilution and each mouse was inoculated with 
two doses of 0.2 ml of the vaccine I/P, 1 week a part. 
Seven days after the second inoculation, all animals 
were challenged via I/P route with 0.1 ml of RVF virus 
containing 103 MIPLD50/ml in addition to other two 
groups of mice, one inoculated with challenge virus 
as positive control and one kept as non-vaccinated non 
challenged negative control. All groups of mice were 
kept under observation for 21 days and deaths were 
recorded daily. The ED50/ml was calculated according 
to the method of [20]. Deaths occurring during the 
1st day were considered as nonspecific.
Determination of challenge protection percentage in 
sheep against FMDV serotypes
Figure-1: Classification of experimental sheep. *The combined vaccine was inoculated S/C at a dose of 1 ml/animal 
inoculated. Each 1 ml dose contain 109 of the Foot and mouth disease virus serotype A, O , SAT2 and 108.5 TCID50 for the 
Rift Valley Fever. **The pregnant ewe were vaccinated with at 2-3 months before parturition.Available at www.veterinaryworld.org/Vol.7/November-2014/4.pdf
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All vaccinated and control positive sheep were 
inoculated with the challenged FMDV either sero-
type A or O or SAT2 with titer 104 BID50 on the base 
of the tongue. All challenged animals were kept 
under daily observation and clinically examined for 
1 week post infection, where lesions on the gum 
and oral mucosa as well as inter digital space were 
recorded. Control negative sheep were included in this 
experiment.
Evaluation of the humeral immune response to the 
prepared combined FMD and RVF vaccine in preg-
nant ewes and their newborn lambs
Serum samples collected from pregnant vac-
cinated ewes before and after parturition, newborn 
lambs from vaccinated ewes and colostrum samples 
from ewes at the 24 hrs. after parturition were tested 
for the presence of antibody titers against the three 
serotypes of FMDV (O pan Asia, A Iran O5 and SAT2/
EGY/2012) and RVFV by SNT using the technique 
described by [25,26] and indirect ELISA according to 
Voller et al. [27].
Results and Discussion
Usually, the attention of vaccine researchers 
directed toward the vaccine evolution aiming to pro-
vide a maximum immunogenicity to livestock, espe-
cially against the most dangerous diseases like FMD 
and RVF. So, the present work succeed to prepare an 
inactivated combined FMD/RVF oil vaccine which 
found to be free from foreign contaminants; safe 
for vaccinated sheep and suckling mice and potent 
inducing adequate protection for vaccinated animals 
and their lambs coming in agreement with the earlier 
report [24].
It was confirmed that the prepared FMD/RVF 
inactivated combined oil vaccine is highly potent 
vaccine providing 80-100% protection of vaccinated 
pregnant ewes against type O, A and SAT2 of FMDV 
as shown in Table-1 and also for the potency of RVF, 
the ED50 was 0.009 which is in aggrement with [28] 
and [29] who said that the permissible limit should not 
be more than 0.02.
Also it was found that vaccinated pregnant ewes 
exhibited detectable antibody titers against all used 
viral antigens by the 1st week post vaccination as deter-
mined by SNT and ELISA (Figures-2 and 3). These 
titers reached their peaks (2.7, 3 & 2.65, 3 and 2.7, 
3.15 by SNT and ELISA for FMD type O, A and SAT2 
respectively) by 10th week post vaccination while those 
of RVF (2.7 and 3.05 by SNT and ELISA respectively 
were recorded by the 12th week post vaccination. 
These levels began to decrease gradually after that to 
record their lowest protective levels (1.5, 1.8; 1.5, 1.8 
and 1.5, 1.75 by SNT and ELISA for FMD type O, A 
and SAT2 respectively) by the 32nd week and those of 
RVF (1.5 and 1.75 by SNT and ELISA respectively) 
by the 34th week post vaccination. These results are 
supported by [30] who reported that oil emulsion 
FMD vaccine provides better results than alhydragel 
FMD vaccine. In addition the obtained results were 
in agreement with that supported previously [26] 
recorded that oil FMD vaccines gave a high and long 
duration immunity with oil FMD vaccine. Also the 
detected RVF antibodies came in parallel course with 
that obtained by [31]. In addition the present results 
agree with those of the earlier report [32] who pre-
pared RVF/FMD combined vaccine which gave a high 
protection percentage against challenge with the vir-
ulent viruses, the earlier report [33] found that there 
were no significant difference between the immune 
response produced by the combined FMD/RVF vac-
cine and that produced by single vaccine against these 
diseases.
The present findings agree with the earlier 
report [34] who found that the Montanide ISA 206 oil 
vaccine can promote long immunity.
It was clear from Figures-4 and 5 that lambs 
born to vaccinated ewes with the prepared combine 
FMD/RVF vaccine had sufficient maternal immunity 
against the included viral antigens transferred to them 
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Figure-2: Mean Antibody titers in pregnant ewes vaccinated 
with combined Foot and Mouth disease/Rift Valley Fever 
vaccine estimated by serum neutralization test.
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through their dam’s colostrum. This immunity appear 
with good levels of specific FMD serotype (O, A and 
SAT2) and RVF antibodies by the 1st week of suck-
ling recorded their peaks by the 6th week then declined 
recorded the lowest protective levels against both anti-
gens by the 12th week of age. The present results were 
higher than that obtained by El-Shehawy et al. [35] who 
reported that the highest FMD antibody titer in serum of 
pregnant ewes was at 4th week post vaccination, FMD 
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Figure-4: Mean antibody titers in newborn lambs from 
vaccinated ewes with combined Foot and Mouth disease/Rift 
Valley Fever vaccine estimated by serum neutralization test.
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Figure-5: Mean antibody titers in newborn lambs from 
vaccinated ewes with combined Foot and Mouth disease/
Rift Valley Fever vaccine estimated by enzyme-linked 
immunosorbent assay.
antibody titer decreased in newborn at the 3rd month of 
age to be non-protective level. Regarding RVF mater-
nal immunity determination through the present work 
showed that it came in agreement with [36,37] who 
stated that RVF antibodies in newly born lambs sera 
remained at protective level for 3 month of age.
Also for complete studying of the maternal 
immunity, mean colostral antibodies were recorded 
as shown in Table-2 that the mean colostral antibody 
titers were higher than serum of ewes at parturition, 
these results go in hand with the results obtained by 
Table-1: FMD lesions and protection percentage in sheep vaccinated with combined FMD/RVF and challenged against the 
three types of FMD virus.
Animal 
number
Animals
tested
Determined FMD lesions
Oral lesion Fore limb Hind limb Challenged 
virus
Tongue Gum Lip L R L R
1
V
a
c
c
i
n
a
t
e
d
 
w
i
t
h
 
c
o
m
b
i
n
e
d
 
F
M
D
/
R
V
F
 
v
a
c
c
i
n
e + - - + - - + FMDV (O)
2 - + - - - - - FMDV (O)
3 - - + - - - - FMDV (O)
4 - + - - - - - FMDV (O)
5 - - - - - - - FMDV (O)
Protection %=80%
6 + - - - - - - FMDV (A)
7 - - - - - - - FMDV (A)
8 - + - - - - - FMDV (A)
9 + - - - - - - FMDV (A)
10 - - + - - - - FMDV (A)
Protection %=100%
11 + - - - - - - FMDV (SAT2)
12 - - + - - - - FMDV (SAT2)
13 + - - - + + - FMDV (SAT2)
14 - + - - - - - FMDV (SAT2)
15 + - - - - - - FMDV (SAT2)
Protection % =80%
16 + + - + + + + FMDV (O)
17 + + + + - + + FMDV (O)
18 + + + - + + + FMDV (A)
19 + + + + + + + FMDV (A)
20 + - + + + + + FMDV (SAT2)
21 - + - + + + - FMDV (SAT2)
22
Control positive (O)
              “
Control positive (A)
              “
Control positive (SAT2)
              “ 
Control negative
              “ 
- - - - - - - No challenge
23 - - - - - - - No challenge
L=Left, R=Right, FMD=Foot and Mouth disease, RVF=Rift Valley fever, FMDV=Foot and Mouth disease virusAvailable at www.veterinaryworld.org/Vol.7/November-2014/4.pdf
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the earlier report [35], who reported that FMD anti-
body level of colostrum was generally higher than that 
in serum of vaccinated dams.
In conclusion, vaccination of pregnant ewes at 
2-3 months before parturition with FMD/RVF combined 
inactivated oil vaccine provide them with high antibody 
titers that could be transferred to their lambs through the 
colostrum and enable the newly born lambs to withstand 
any FMD and RVF infections for at least 3-4 months of 
age and depending on the previous results, the newly 
born lambs should be vaccinated at this age.
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